[Value of 18F-FDG PET imaging in diagnosing tumor residue of intracranial glioma after surgery and radiotherapy].
OBJECTIVE
It is difficult to diagnose tumor residue by CT/MRI after treatment. The application of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) to determine the suspected tumor residue after treatment has become a hot target in the study of radiotherapy. This study was designed to discuss the clinical value of (18)-FDG PET imaging in post-operative and post-radiotherapeutic intracranial glioma.


METHODS
(18)F-FDG PET imaging was performed in 23 patients with post-operative and post-radio-therapeutic intracranial glioma, and compared with CT/MRI. The final diagnosis of tumor residue was proved by pathology or clinical follow-up.


RESULTS
Of 23 patients, 12 showed (18)F-FDG PET positive, and 11 showed negative,among which 3 were false negative. The accuracy of (18)F-FDG PET was 87.0% (20/23), significantly higher than 60.9% (14/23) of CT/MRI scan (P< 0.05). The diagnosis of tumor residue in 9 patients cannot be determined by CT/MRI, while 4 of these patients showed (18)F-FDG PET positive, and the other 5 showed (18)F-FDG PET negative. Eight of 23 patients diagnosed tumor residues by CT/MRI, showed (18)F-FDG PET positive,too. Six patients,diagnosed by CT/MRI as radioactive-disease sufferers, and PET indicated with low or deficient FDG metabolism, were proved to have radioactive diseases by follow-up.


CONCLUSIONS
(18)F-FDG PET imaging has significant dominance in characterizing lesions,and differentiating tumor residue in post-operative and post-radiotherapeutic intracranial glioma. Combined with CT and MRI, it can provide both anatomical and functional information for treatment.
Department of Radiation Oncology, People's Hospital of Guangdong province, Guangzhou, P.R. China.
Ying-Rui
YR
Chen
Wei-Xiong
WX
Li
Ying-Ru
YR
Lin
Long-Hua
LH
Chen
D000328:Adult; D001254:Astrocytoma / Q000000981:diagnostic imaging / Q000532:radiotherapy / Q000601:surgery; D001932:Brain Neoplasms / Q000000981:diagnostic imaging* / Q000532:radiotherapy / Q000601:surgery; D005260:Female; D019788:Fluorodeoxyglucose F18; D005910:Glioma / Q000000981:diagnostic imaging* / Q000532:radiotherapy / Q000601:surgery; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18